文献速递胸部肿瘤放疗

左前降支冠状动脉放疗剂量与NRG肿瘤学RTOG 0617试验全因死亡率的关联

Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-11-24

该研究基于NRG肿瘤学/RTOG 0617试验数据,手工勾画左前降支冠状动脉,分析其V15 Gy与全因死亡率的关系。449例可评估患者中,左前降支V15 Gy≥10%较<10%与全因死亡率升高相关(HR 1.43,95%CI 1.02-1.99,P=0.037),中位总生存分别为20.2个月与25.1个月。

要点

  • 左前降支V15 Gy≥10%与全因死亡率升高独立相关(HR 1.43,95%CI 1.02-1.99,P=0.037)。
  • 左前降支V15 Gy≥10%组中位总生存20.2个月,<10%组25.1个月,2年总生存率分别为47%与67%(P=0.004)。
  • 平均心脏剂量≥10 Gy与<10 Gy相比,全因死亡率无显著差异(校正HR 1.12,95%CI 0.88-1.43,P=0.36)。

核心结论

  • 在RTOG 0617再分析中,左前降支V15 Gy≥10%与全因死亡率升高相关。

研究设计与样本

  • 使用NRG肿瘤学/RTOG 0617来自国家临床试验网络的数据集,手工勾画左前降支冠状动脉,采用多变量Cox回归校正已知预后因素,并用Kaplan-Meier法估算总生存。
  • 共449例患者具备左前降支剂量体积数据与临床结局,排除10例因左前降支剂量统计不可靠者。
  • 基线心血管风险评估仅纳入年龄、性别和吸烟史。

主要发现

  • 患者中位年龄64岁,左前降支V15 Gy中位值为38%(四分位距15%-62%)。
  • 左前降支V15 Gy<10%者94例(21%),≥10%者355例(79%)。
  • 校正预后因素后,左前降支V15 Gy≥10%较<10%与全因死亡率升高相关(HR 1.43,95%CI 1.02-1.99,P=0.037)。
  • 平均心脏剂量≥10 Gy较<10 Gy与全因死亡率无显著关联(校正HR 1.12,95%CI 0.88-1.43,P=0.36)。
  • 左前降支V15 Gy≥10%组与<10%组的中位总生存分别为20.2个月与25.1个月,2年总生存率分别为47%与67%(P=0.004)。

临床怎么用

  • 作者认为这些发现强调需要改进心脏风险分层并采取积极的风险缓解策略,包括在国家指南和临床试验中实施心脏亚结构剂量约束。

局限性

  • 基线心血管风险评估仅可获得年龄、性别和吸烟史。
  • 该剂量约束尚未在独立或前瞻性数据集中得到验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A left anterior descending (LAD) coronary artery volume (V) receiving 15 Gy (V15 Gy) ≥10% has been recently observed to be an independent risk factor of major adverse cardiac events and all-cause mortality in patients with locally advanced non-small cell lung cancer treated with radiation therapy. However, this dose constraint has not been validated in independent or prospective data sets. METHODS AND MATERIALS: The NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0617 data set from the National Clinical Trials Network was used. The LAD coronary artery was manually contoured. Multivariable Cox regression was performed, adjusting for known prognostic factors. Kaplan-Meier estimates of overall survival (OS) were calculated. For assessment of baseline cardiovascular risk, only age, sex, and smoking history were available. RESULTS: There were 449 patients with LAD dose-volume data and clinical outcomes available after 10 patients were excluded owing to unreliable LAD dose statistics. The median age was 64 years. The median LAD V15 Gy was 38% (interquartile range, 15%-62%), including 94 patients (21%) with LAD V15 Gy <10% and 355 (79%) with LAD V15 Gy ≥10%. Adjusting for prognostic factors, LAD V15 Gy ≥10% versus <10% was associated with an increased risk of all-cause mortality (hazard ratio [HR], 1.43; 95% confidence interval, 1.02-1.99; P = .037), whereas a mean heart dose ≥10 Gy versus <10 Gy was not (adjusted HR, 1.12; 95% confidence interval, 0.88-1.43; P = .36). The median OS for patients with LAD V15 Gy ≥10% versus <10% was 20.2 versus 25.1 months, respectively, with 2-year OS estimates of 47% versus 67% (P = .004), respectively. CONCLUSIONS: In a reanalysis of RTOG 0617, LAD V15 Gy ≥10% was associated with an increased risk of all-cause mortality. These findings underscore the need for improved cardiac risk stratification and aggressive risk mitigation strategies, including implementation of cardiac substructure dose constraints in national guidelines and clinical trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McKenzie E, Zhang S, Zakariaee R, et al. Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617. Int J Radiat Oncol Biol Phys. 2022. PMID: 36436615. doi:10.1016/j.ijrobp.2022.11.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。